The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

References

• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001447. DOI: 10.1002/14651858.CD001447.pub2.
   Web of Science ®Google Scholar
• Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, . The epidemiology of ALS and the role of population based registries. BBA. 2006;1762:1150–7.
   PubMed Web of Science ®Google Scholar
• Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G, PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003;74:1258–61.
   PubMed Web of Science ®Google Scholar
• Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988. Arch Neurol. 1991;48:589–93.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population based study. Arch Neurol. 2000;57: 109–13.
   PubMed Web of Science ®Google Scholar
• Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry. 1996;60:147–50.
   PubMed Web of Science ®Google Scholar
• McGuire V, Longstreth WT Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology. 1996; 47:571–3.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population based study. Neurology. 1999;52: 504–9.
   PubMed Web of Science ®Google Scholar
• Piemonte and Valle d'Aosta Register for Amyotrophic Lateral Sclerosis (PARALS). Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology. 2001;56:239–44.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone IL, . Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. J Neurol Neurosurg Psychiatry. 2005;76:1094–8.
   PubMed Web of Science ®Google Scholar
• Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G; SLALOM Group. Incidence of ALS in Lombardy, Italy. Neurology. 2007;68:141–5.
   PubMed Web of Science ®Google Scholar
• Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev. 1995;17: 243–64.
   PubMed Web of Science ®Google Scholar
• Preux PM, Druet-Cabanac M, Couratier P, Debrock C, Troung T, Marcharia W, . Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. J Clin Epidemiol. 2000;53:1025–9.
   PubMed Web of Science ®Google Scholar
• Coffman CJ, Horner RD, Grambow SC, Lindquist J, VA Cooperative Studies Program Project No. 500. Estimating the occurrence of amyotrophic lateral sclerosis among Gulf War (1990–1991) veterans using capture-recapture methods. Neuroepidemiology. 2005;24:141–50.
   PubMed Web of Science ®Google Scholar
• Beghi E, Mennini T, Bendotti C, Bigini P, Logroscino G, Chiò A, . The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14:3185–200.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG on behalf of the EURALS Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler Other Motor Neuron Disord. 2008;9: 1–14.
   Google Scholar
• Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8: 94–109.
   PubMed Web of Science ®Google Scholar
• Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103–15.
   PubMed Web of Science ®Google Scholar
• Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, . Can we eliminate placebo in ALS clinical trials? Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:11–5.
   PubMed Web of Science ®Google Scholar
• Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology. 1993;43:751–5.
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD002064. DOI: 10.1002/14651858.CD002064.pub2.
   Web of Science ®Google Scholar
• Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: descriptive and preliminary experience. Ann Neurol. 1987;22:328–33.
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, . Subcutaneous IGF-1 is not beneficial in a two-year ALS trial. Neurology. 2008;71: 1770–5.
   PubMed Web of Science ®Google Scholar
• Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002829. DOI: 10.1002/14651858.CD002829.pub4.
   Google Scholar
• Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004302. DOI:10.1002/14651858.CD004302.pub2.
   Google Scholar
• Langmore SE, Kasarskis EJ, Manca ML, Olney RK. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004030. DOI:10.1002/14651858.CD004030.pub2.
   Google Scholar
• Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004156. DOI:10.1002/14651858.CD004156.pub3.
   Google Scholar
• Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–7.
   PubMed Web of Science ®Google Scholar
• Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A for the SLALOM Group. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2008;9:163–7.
   PubMed Web of Science ®Google Scholar
• The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis. Neurology. 1993;43: 2466–70.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Aids to the investigation of peripheral nerve injuries – War memorandum. 2nd edn. London: HSMO; 1943:11–46.
   Google Scholar
• Norris FH Jr, Calanchini PR, Fallar RJ, Pancharis S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721–8.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Montes J, Buchsbaum A, Barsdorf AI, Battista V, . and QALS Study Group. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicentre clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2007;8:42–6.
   PubMed Web of Science ®Google Scholar
• Beghi E. 127th ENMC International Workshop: implementation of a European registry of ALS. Naarden, The Netherlands, 8–10 October 2004. Neuromuscul Disord. 2006;16:46–53.
   PubMedGoogle Scholar
• Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, . Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67:20–7.
   PubMed Web of Science ®Google Scholar